View Future GrowthAether Industries 過去の業績過去 基準チェック /46Aether Industriesは、平均年間16.1%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間14.2% 15.6%収益成長率で 成長しています。 Aether Industriesの自己資本利益率は8.9%であり、純利益率は18.9%です。主要情報16.07%収益成長率10.53%EPS成長率Pharmaceuticals 業界の成長17.49%収益成長率15.58%株主資本利益率8.94%ネット・マージン18.92%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 18Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.55 (up from ₹11.95 in FY 2025). Revenue: ₹11.8b (up 41% from FY 2025). Net income: ₹2.19b (up 39% from FY 2025). Profit margin: 19% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • May 05Aether Industries Limited to Report Q4, 2026 Results on May 15, 2026Aether Industries Limited announced that they will report Q4, 2026 results on May 15, 2026Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.86 (up from ₹3.27 in 3Q 2025). Revenue: ₹3.17b (up 44% from 3Q 2025). Net income: ₹644.8m (up 49% from 3Q 2025). Profit margin: 20% (in line with 3Q 2025). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 21Aether Industries Limited to Report Q3, 2026 Results on Feb 03, 2026Aether Industries Limited announced that they will report Q3, 2026 results on Feb 03, 2026Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹4.07 (vs ₹2.63 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.07 (up from ₹2.63 in 2Q 2025). Revenue: ₹2.84b (up 43% from 2Q 2025). Net income: ₹539.6m (up 55% from 2Q 2025). Profit margin: 19% (up from 18% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Oct 04Aether Industries Limited to Report Q2, 2026 Results on Nov 13, 2025Aether Industries Limited announced that they will report Q2, 2026 results on Nov 13, 2025すべての更新を表示Recent updatesReported Earnings • May 18Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.55 (up from ₹11.95 in FY 2025). Revenue: ₹11.8b (up 41% from FY 2025). Net income: ₹2.19b (up 39% from FY 2025). Profit margin: 19% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • May 05Aether Industries Limited to Report Q4, 2026 Results on May 15, 2026Aether Industries Limited announced that they will report Q4, 2026 results on May 15, 2026Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,161, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past three years.Price Target Changed • Feb 05Price target increased by 10.0% to ₹1,154Up from ₹1,049, the current price target is an average from 5 analysts. New target price is 13% above last closing price of ₹1,023. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₹17.58 for next year compared to ₹11.95 last year.Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.86 (up from ₹3.27 in 3Q 2025). Revenue: ₹3.17b (up 44% from 3Q 2025). Net income: ₹644.8m (up 49% from 3Q 2025). Profit margin: 20% (in line with 3Q 2025). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 21Aether Industries Limited to Report Q3, 2026 Results on Feb 03, 2026Aether Industries Limited announced that they will report Q3, 2026 results on Feb 03, 2026Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹1,000, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past three years.Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹893, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 2.1% over the past three years.Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹4.07 (vs ₹2.63 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.07 (up from ₹2.63 in 2Q 2025). Revenue: ₹2.84b (up 43% from 2Q 2025). Net income: ₹539.6m (up 55% from 2Q 2025). Profit margin: 19% (up from 18% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Oct 04Aether Industries Limited to Report Q2, 2026 Results on Nov 13, 2025Aether Industries Limited announced that they will report Q2, 2026 results on Nov 13, 2025Reported Earnings • Jul 25First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: ₹3.55 (up from ₹2.26 in 1Q 2025). Revenue: ₹2.59b (up 44% from 1Q 2025). Net income: ₹470.2m (up 57% from 1Q 2025). Profit margin: 18% (up from 17% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.お知らせ • Jul 24Aether Industries Limited, Annual General Meeting, Sep 12, 2025Aether Industries Limited, Annual General Meeting, Sep 12, 2025.お知らせ • Jun 30Aether Industries Limited to Report Q1, 2026 Results on Jul 24, 2025Aether Industries Limited announced that they will report Q1, 2026 results on Jul 24, 2025お知らせ • May 15An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion.An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion on May 14, 2025. A cash consideration valued at INR 700 per share will be paid for 8.979173 million shares. An undisclosed buyer completed the acquisition of 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai on May 14, 2025.New Risk • May 08New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Reported Earnings • May 03Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ₹11.95 (up from ₹6.31 in FY 2024). Revenue: ₹8.80b (up 47% from FY 2024). Net income: ₹1.58b (up 92% from FY 2024). Profit margin: 18% (up from 14% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.お知らせ • Apr 26Aether Industries Limited to Report Q4, 2025 Results on May 02, 2025Aether Industries Limited announced that they will report Q4, 2025 results on May 02, 2025Board Change • Apr 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 17Aether Industries Limited Provides Revenue Guidance for the Financial Year 2024Aether Industries Limited provided revenue guidance for the financial year 2024. The company anticipates net financial year to close to reach a revenue of INR 400 million.お知らせ • Jan 09Aether Industries Limited Announces Revocation Order from GPCB for Resumption of Operations at Manufacturing Facility IIAether Industries Limited announced that the Gujarat Pollution Control Board (GPCB), through its communication received January 9, 2025, has revoked the closure order issued on November 29, 2023, following the fire incident, for Manufacturing Facility II. Consequently, the facility is now approved for 100% resumption of operations. The Company will commence full-capacity operations at Manufacturing Facility II upon ensuring compliance with the stipulated conditions.お知らせ • Jan 01Aether Industries Limited to Report Q3, 2025 Results on Jan 17, 2025Aether Industries Limited announced that they will report Q3, 2025 results on Jan 17, 2025Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 19Second quarter 2025 earnings released: EPS: ₹2.87 (vs ₹2.77 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.87 (up from ₹2.77 in 2Q 2024). Revenue: ₹2.09b (up 27% from 2Q 2024). Net income: ₹380.7m (up 3.8% from 2Q 2024). Profit margin: 18% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.お知らせ • Oct 04Aether Industries Limited to Report Q2, 2025 Results on Oct 18, 2024Aether Industries Limited announced that they will report Q2, 2025 results on Oct 18, 2024お知らせ • Jul 22Aether Industries Limited, Annual General Meeting, Sep 10, 2024Aether Industries Limited, Annual General Meeting, Sep 10, 2024.Reported Earnings • Jul 21First quarter 2025 earnings released: EPS: ₹2.26 (vs ₹2.25 in 1Q 2024)First quarter 2025 results: EPS: ₹2.26 (up from ₹2.25 in 1Q 2024). Revenue: ₹1.80b (up 12% from 1Q 2024). Net income: ₹299.3m (flat on 1Q 2024). Profit margin: 17% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India.お知らせ • Jul 04Aether Industries Limited to Report Q1, 2025 Results on Jul 19, 2024Aether Industries Limited announced that they will report Q1, 2025 results on Jul 19, 2024New Risk • Jun 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 20% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: ₹1.32 (vs ₹2.81 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.32 (down from ₹2.81 in 3Q 2023). Revenue: ₹1.67b (flat on 3Q 2023). Net income: ₹174.3m (down 50% from 3Q 2023). Profit margin: 11% (down from 21% in 3Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.お知らせ • Jan 16Aether Industries Limited to Report Q3, 2024 Results on Feb 01, 2024Aether Industries Limited announced that they will report Q3, 2024 results on Feb 01, 2024Reported Earnings • Nov 02Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: EPS: ₹2.77 (up from ₹2.19 in 2Q 2023). Revenue: ₹1.78b (up 27% from 2Q 2023). Net income: ₹366.8m (up 35% from 2Q 2023). Profit margin: 21% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.お知らせ • Oct 20Aether Industries Limited to Report Q2, 2024 Results on Oct 31, 2023Aether Industries Limited announced that they will report Q2, 2024 results on Oct 31, 2023Reported Earnings • Jul 27First quarter 2024 earnings released: EPS: ₹2.25 (vs ₹2.46 in 1Q 2023)First quarter 2024 results: EPS: ₹2.25 (down from ₹2.46 in 1Q 2023). Revenue: ₹1.61b (flat on 1Q 2023). Net income: ₹298.1m (down 2.6% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.お知らせ • Jul 12Aether Industries Limited to Report Q1, 2024 Results on Jul 26, 2023Aether Industries Limited announced that they will report Q1, 2024 results on Jul 26, 2023New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Shareholders have been diluted in the past year (6.5% increase in shares outstanding).お知らせ • Jun 24Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion.Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 8,012,820 Price\Range: INR 936 Transaction Features: Regulation S; Subsequent Direct ListingReported Earnings • May 08Full year 2023 earnings released: EPS: ₹10.47 (vs ₹9.67 in FY 2022)Full year 2023 results: EPS: ₹10.47 (up from ₹9.67 in FY 2022). Revenue: ₹6.68b (up 13% from FY 2022). Net income: ₹1.30b (up 20% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.お知らせ • May 07Aether Industries Limited, Annual General Meeting, Jun 16, 2023Aether Industries Limited, Annual General Meeting, Jun 16, 2023.Reported Earnings • Jan 22Third quarter 2023 earnings released: EPS: ₹2.81 (vs ₹2.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.81 (up from ₹2.28 in 3Q 2022). Revenue: ₹1.67b (up 10% from 3Q 2022). Net income: ₹350.4m (up 38% from 3Q 2022). Profit margin: 21% (up from 17% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.お知らせ • Jan 21Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat.Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat on January 20, 2023. The transaction will be funded by internal accruals and funding from banks. Aether Industries Limited (NSEI:AETHER) Completed the acquisition of Industrial premises in Gujarat on January 20, 2023.お知らせ • Jan 02Aether Industries Limited to Report Q3, 2023 Results on Jan 20, 2023Aether Industries Limited announced that they will report Q3, 2023 results on Jan 20, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹2.27 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.40b (flat on 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 18% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹24.93 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.47b (up 1.5% from 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 17% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.お知らせ • Nov 05Aether Industries Limited to Report Q2, 2023 Results on Nov 11, 2022Aether Industries Limited announced that they will report Q2, 2023 results on Nov 11, 2022Reported Earnings • Jul 27First quarter 2023 earnings released: EPS: ₹2.46 (vs ₹3.34 in 1Q 2022)First quarter 2023 results: EPS: ₹2.46 (down from ₹3.34 in 1Q 2022). Revenue: ₹1.63b (up 8.3% from 1Q 2022). Net income: ₹306.2m (down 5.3% from 1Q 2022). Profit margin: 19% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses.お知らせ • Jul 26Aether Industries Limited, Annual General Meeting, Sep 27, 2022Aether Industries Limited, Annual General Meeting, Sep 27, 2022.お知らせ • Jul 19Aether Industries Limited to Report Q1, 2023 Results on Jul 25, 2022Aether Industries Limited announced that they will report Q1, 2023 results on Jul 25, 2022お知らせ • Jun 17Aether Industries Limited Approves Committee ChangesThe board of Aether Industries Limited in their Meeting held on 16th June, 2022, approved the resignation of Ms. Purnima Ashwin Desai and appointment of Mr. Jitendra Popatlal Vakharia as the audit committee member.Reported Earnings • Jun 17Third quarter 2022 earnings releasedThird quarter 2022 results: EPS: ₹2.28. Revenue: ₹1.51b (flat on 3Q 2021). Net income: ₹254.0m (up ₹254.0m from 3Q 2021). Profit margin: 17% (up from null in 3Q 2021).お知らせ • Jun 09Aether Industries Limited to Report Q4, 2022 Results on Jun 16, 2022Aether Industries Limited announced that they will report Q4, 2022 results on Jun 16, 2022収支内訳Aether Industries の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BSE:543534 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 2611,6012,195627031 Dec 2510,9542,158566030 Sep 259,9301,947492030 Jun 259,1481,755452031 Mar 258,4051,584435031 Dec 247,1741,067440030 Sep 246,531807393030 Jun 246,171826406031 Mar 245,995825390031 Dec 236,6781,215367030 Sep 236,7951,391391030 Jun 236,5551,296355031 Mar 236,5441,304351031 Dec 226,1751,189313030 Sep 226,0161,092291030 Jun 226,0521,072281031 Mar 225,9271,089272031 Dec 215,6101,058278030 Sep 215,186956268030 Jun 214,884869238031 Mar 214,517711228031 Mar 203,026400138031 Mar 192,019233110031 Mar 181,08778880質の高い収益: 543534 非現金収入 のレベルが高いです。利益率の向上: 543534の現在の純利益率 (18.9%)は、昨年(18.8%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 543534の収益は過去 5 年間で年間16.1%増加しました。成長の加速: 543534の過去 1 年間の収益成長率 ( 38.5% ) は、5 年間の平均 ( 年間16.1%を上回っています。収益対業界: 543534の過去 1 年間の収益成長率 ( 38.5% ) はPharmaceuticals業界15.9%を上回りました。株主資本利益率高いROE: 543534の 自己資本利益率 ( 8.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/05 07:01終値2026/07/03 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aether Industries Limited 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Kumar Saumya SinghAmbit CapitalAshwin MehtaAmbit Capitalnull nullAsian Markets Securities Private Limited9 その他のアナリストを表示
Reported Earnings • May 18Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.55 (up from ₹11.95 in FY 2025). Revenue: ₹11.8b (up 41% from FY 2025). Net income: ₹2.19b (up 39% from FY 2025). Profit margin: 19% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • May 05Aether Industries Limited to Report Q4, 2026 Results on May 15, 2026Aether Industries Limited announced that they will report Q4, 2026 results on May 15, 2026
Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.86 (up from ₹3.27 in 3Q 2025). Revenue: ₹3.17b (up 44% from 3Q 2025). Net income: ₹644.8m (up 49% from 3Q 2025). Profit margin: 20% (in line with 3Q 2025). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 21Aether Industries Limited to Report Q3, 2026 Results on Feb 03, 2026Aether Industries Limited announced that they will report Q3, 2026 results on Feb 03, 2026
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹4.07 (vs ₹2.63 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.07 (up from ₹2.63 in 2Q 2025). Revenue: ₹2.84b (up 43% from 2Q 2025). Net income: ₹539.6m (up 55% from 2Q 2025). Profit margin: 19% (up from 18% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Oct 04Aether Industries Limited to Report Q2, 2026 Results on Nov 13, 2025Aether Industries Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Reported Earnings • May 18Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹16.55 (up from ₹11.95 in FY 2025). Revenue: ₹11.8b (up 41% from FY 2025). Net income: ₹2.19b (up 39% from FY 2025). Profit margin: 19% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.0%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • May 05Aether Industries Limited to Report Q4, 2026 Results on May 15, 2026Aether Industries Limited announced that they will report Q4, 2026 results on May 15, 2026
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹1,161, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past three years.
Price Target Changed • Feb 05Price target increased by 10.0% to ₹1,154Up from ₹1,049, the current price target is an average from 5 analysts. New target price is 13% above last closing price of ₹1,023. Stock is up 20% over the past year. The company is forecast to post earnings per share of ₹17.58 for next year compared to ₹11.95 last year.
Reported Earnings • Feb 04Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.86 (up from ₹3.27 in 3Q 2025). Revenue: ₹3.17b (up 44% from 3Q 2025). Net income: ₹644.8m (up 49% from 3Q 2025). Profit margin: 20% (in line with 3Q 2025). Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 21Aether Industries Limited to Report Q3, 2026 Results on Feb 03, 2026Aether Industries Limited announced that they will report Q3, 2026 results on Feb 03, 2026
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹1,000, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 16% over the past three years.
Valuation Update With 7 Day Price Move • Nov 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹893, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 2.1% over the past three years.
Reported Earnings • Nov 14Second quarter 2026 earnings released: EPS: ₹4.07 (vs ₹2.63 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.07 (up from ₹2.63 in 2Q 2025). Revenue: ₹2.84b (up 43% from 2Q 2025). Net income: ₹539.6m (up 55% from 2Q 2025). Profit margin: 19% (up from 18% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Oct 04Aether Industries Limited to Report Q2, 2026 Results on Nov 13, 2025Aether Industries Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Reported Earnings • Jul 25First quarter 2026 earnings: EPS exceeds analyst expectationsFirst quarter 2026 results: EPS: ₹3.55 (up from ₹2.26 in 1Q 2025). Revenue: ₹2.59b (up 44% from 1Q 2025). Net income: ₹470.2m (up 57% from 1Q 2025). Profit margin: 18% (up from 17% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.4%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • Jul 24Aether Industries Limited, Annual General Meeting, Sep 12, 2025Aether Industries Limited, Annual General Meeting, Sep 12, 2025.
お知らせ • Jun 30Aether Industries Limited to Report Q1, 2026 Results on Jul 24, 2025Aether Industries Limited announced that they will report Q1, 2026 results on Jul 24, 2025
お知らせ • May 15An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion.An undisclosed buyer acquired 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai for INR 6.3 billion on May 14, 2025. A cash consideration valued at INR 700 per share will be paid for 8.979173 million shares. An undisclosed buyer completed the acquisition of 6.77% stake in Aether Industries Limited (NSEI:AETHER) from Purnima Ashwin Desai on May 14, 2025.
New Risk • May 08New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 27% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Reported Earnings • May 03Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ₹11.95 (up from ₹6.31 in FY 2024). Revenue: ₹8.80b (up 47% from FY 2024). Net income: ₹1.58b (up 92% from FY 2024). Profit margin: 18% (up from 14% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 4.7%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Apr 26Aether Industries Limited to Report Q4, 2025 Results on May 02, 2025Aether Industries Limited announced that they will report Q4, 2025 results on May 02, 2025
Board Change • Apr 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 17Aether Industries Limited Provides Revenue Guidance for the Financial Year 2024Aether Industries Limited provided revenue guidance for the financial year 2024. The company anticipates net financial year to close to reach a revenue of INR 400 million.
お知らせ • Jan 09Aether Industries Limited Announces Revocation Order from GPCB for Resumption of Operations at Manufacturing Facility IIAether Industries Limited announced that the Gujarat Pollution Control Board (GPCB), through its communication received January 9, 2025, has revoked the closure order issued on November 29, 2023, following the fire incident, for Manufacturing Facility II. Consequently, the facility is now approved for 100% resumption of operations. The Company will commence full-capacity operations at Manufacturing Facility II upon ensuring compliance with the stipulated conditions.
お知らせ • Jan 01Aether Industries Limited to Report Q3, 2025 Results on Jan 17, 2025Aether Industries Limited announced that they will report Q3, 2025 results on Jan 17, 2025
Board Change • Dec 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Non-Executive Independent Director Rajkumar Borana was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 19Second quarter 2025 earnings released: EPS: ₹2.87 (vs ₹2.77 in 2Q 2024)Second quarter 2025 results: EPS: ₹2.87 (up from ₹2.77 in 2Q 2024). Revenue: ₹2.09b (up 27% from 2Q 2024). Net income: ₹380.7m (up 3.8% from 2Q 2024). Profit margin: 18% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Oct 04Aether Industries Limited to Report Q2, 2025 Results on Oct 18, 2024Aether Industries Limited announced that they will report Q2, 2025 results on Oct 18, 2024
お知らせ • Jul 22Aether Industries Limited, Annual General Meeting, Sep 10, 2024Aether Industries Limited, Annual General Meeting, Sep 10, 2024.
Reported Earnings • Jul 21First quarter 2025 earnings released: EPS: ₹2.26 (vs ₹2.25 in 1Q 2024)First quarter 2025 results: EPS: ₹2.26 (up from ₹2.25 in 1Q 2024). Revenue: ₹1.80b (up 12% from 1Q 2024). Net income: ₹299.3m (flat on 1Q 2024). Profit margin: 17% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Jul 04Aether Industries Limited to Report Q1, 2025 Results on Jul 19, 2024Aether Industries Limited announced that they will report Q1, 2025 results on Jul 19, 2024
New Risk • Jun 05New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 14% Last year net profit margin: 20% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (14% net profit margin). Shareholders have been diluted in the past year (6.5% increase in shares outstanding).
Reported Earnings • Feb 02Third quarter 2024 earnings released: EPS: ₹1.32 (vs ₹2.81 in 3Q 2023)Third quarter 2024 results: EPS: ₹1.32 (down from ₹2.81 in 3Q 2023). Revenue: ₹1.67b (flat on 3Q 2023). Net income: ₹174.3m (down 50% from 3Q 2023). Profit margin: 11% (down from 21% in 3Q 2023). Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Jan 16Aether Industries Limited to Report Q3, 2024 Results on Feb 01, 2024Aether Industries Limited announced that they will report Q3, 2024 results on Feb 01, 2024
Reported Earnings • Nov 02Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: EPS: ₹2.77 (up from ₹2.19 in 2Q 2023). Revenue: ₹1.78b (up 27% from 2Q 2023). Net income: ₹366.8m (up 35% from 2Q 2023). Profit margin: 21% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Oct 20Aether Industries Limited to Report Q2, 2024 Results on Oct 31, 2023Aether Industries Limited announced that they will report Q2, 2024 results on Oct 31, 2023
Reported Earnings • Jul 27First quarter 2024 earnings released: EPS: ₹2.25 (vs ₹2.46 in 1Q 2023)First quarter 2024 results: EPS: ₹2.25 (down from ₹2.46 in 1Q 2023). Revenue: ₹1.61b (flat on 1Q 2023). Net income: ₹298.1m (down 2.6% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Jul 12Aether Industries Limited to Report Q1, 2024 Results on Jul 26, 2023Aether Industries Limited announced that they will report Q1, 2024 results on Jul 26, 2023
New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risk Shareholders have been diluted in the past year (6.5% increase in shares outstanding).
お知らせ • Jun 24Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion.Aether Industries Limited has completed a Follow-on Equity Offering in the amount of INR 7.5 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 8,012,820 Price\Range: INR 936 Transaction Features: Regulation S; Subsequent Direct Listing
Reported Earnings • May 08Full year 2023 earnings released: EPS: ₹10.47 (vs ₹9.67 in FY 2022)Full year 2023 results: EPS: ₹10.47 (up from ₹9.67 in FY 2022). Revenue: ₹6.68b (up 13% from FY 2022). Net income: ₹1.30b (up 20% from FY 2022). Profit margin: 20% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
お知らせ • May 07Aether Industries Limited, Annual General Meeting, Jun 16, 2023Aether Industries Limited, Annual General Meeting, Jun 16, 2023.
Reported Earnings • Jan 22Third quarter 2023 earnings released: EPS: ₹2.81 (vs ₹2.28 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.81 (up from ₹2.28 in 3Q 2022). Revenue: ₹1.67b (up 10% from 3Q 2022). Net income: ₹350.4m (up 38% from 3Q 2022). Profit margin: 21% (up from 17% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Jan 21Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat.Aether Industries Limited (NSEI:AETHER) acquired Industrial premises in Gujarat on January 20, 2023. The transaction will be funded by internal accruals and funding from banks. Aether Industries Limited (NSEI:AETHER) Completed the acquisition of Industrial premises in Gujarat on January 20, 2023.
お知らせ • Jan 02Aether Industries Limited to Report Q3, 2023 Results on Jan 20, 2023Aether Industries Limited announced that they will report Q3, 2023 results on Jan 20, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹2.27 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.40b (flat on 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 18% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹2.19 (vs ₹24.93 in 2Q 2022)Second quarter 2023 results: EPS: ₹2.19. Revenue: ₹1.47b (up 1.5% from 2Q 2022). Net income: ₹272.0m (up 8.0% from 2Q 2022). Profit margin: 19% (up from 17% in 2Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.
お知らせ • Nov 05Aether Industries Limited to Report Q2, 2023 Results on Nov 11, 2022Aether Industries Limited announced that they will report Q2, 2023 results on Nov 11, 2022
Reported Earnings • Jul 27First quarter 2023 earnings released: EPS: ₹2.46 (vs ₹3.34 in 1Q 2022)First quarter 2023 results: EPS: ₹2.46 (down from ₹3.34 in 1Q 2022). Revenue: ₹1.63b (up 8.3% from 1Q 2022). Net income: ₹306.2m (down 5.3% from 1Q 2022). Profit margin: 19% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses.
お知らせ • Jul 26Aether Industries Limited, Annual General Meeting, Sep 27, 2022Aether Industries Limited, Annual General Meeting, Sep 27, 2022.
お知らせ • Jul 19Aether Industries Limited to Report Q1, 2023 Results on Jul 25, 2022Aether Industries Limited announced that they will report Q1, 2023 results on Jul 25, 2022
お知らせ • Jun 17Aether Industries Limited Approves Committee ChangesThe board of Aether Industries Limited in their Meeting held on 16th June, 2022, approved the resignation of Ms. Purnima Ashwin Desai and appointment of Mr. Jitendra Popatlal Vakharia as the audit committee member.
Reported Earnings • Jun 17Third quarter 2022 earnings releasedThird quarter 2022 results: EPS: ₹2.28. Revenue: ₹1.51b (flat on 3Q 2021). Net income: ₹254.0m (up ₹254.0m from 3Q 2021). Profit margin: 17% (up from null in 3Q 2021).
お知らせ • Jun 09Aether Industries Limited to Report Q4, 2022 Results on Jun 16, 2022Aether Industries Limited announced that they will report Q4, 2022 results on Jun 16, 2022